Klinicheskiy sluchay: primenenie selektivnogo antagonistaretseptorov endotelina ambrizentana pri idiopaticheskoy legochnoy gipertenzii
- Authors: Andreeva Y.A1, Martynyuk TV1, Ataullakhanova DM1, Lazutkina VK1, Korobkova IZ1, Sakhnova TA1, Blinova EV1, Danilov NM1, Nakonechnikov SN1, Chazova IE1
-
Affiliations:
- Issue: Vol 5, No 1 (2008)
- Pages: 57-64
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/28812
- DOI: https://doi.org/10.26442/SG28812
- ID: 28812
Cite item
Full Text
Abstract
About the authors
Yu A Andreeva
T V Martynyuk
D M Ataullakhanova
V K Lazutkina
I Z Korobkova
T A Sakhnova
E V Blinova
N M Danilov
S N Nakonechnikov
I E Chazova
References
- Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия. М.: Нолидж, 1999.
- Диагностика и лечение легочной гипертензии. Российские рекомендации ВНОК. М., 2007.
- Rubin et al. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11: 991
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
- Clozel M. Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 2000; 35: S65.
- Gali_ N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-35.
- Battistini B, Berthiaume N, Kelland NF et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood). 2006; 231 (6): 653-95.
- Olschewski H, Galie N, Kramer M et al. Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study. San Diego, CA: American Thoracic Society, 2006.